| Literature DB >> 34204339 |
Roxana Jijie1,2, Gabriela Mihalache3,4, Ioana-Miruna Balmus2, Stefan-Adrian Strungaru2, Emanuel Stefan Baltag1, Alin Ciobica5, Mircea Nicoara5,6, Caterina Faggio7.
Abstract
The overuse of antibiotics combined with the limitation of wastewater facilities has resulted in drug residue accumulation in the natural environment. Thus, in recent years, the presence of antibiotic residues in the environment has raised concerns over the potential harmful effects on ecosystems and human health. The in vivo studies represent an essential step to study the potential impact induced by pharmaceutical exposure. Due to the limitations of traditional vertebrate model systems, zebrafish (Danio rerio) has recently emerged as a promising animal model to study the toxic effects of drugs and their therapeutic efficacy. The present review summarizes the recent advances made on the toxicity of seven representative classes of antibiotics, namely aminoglycosides, β-lactams, macrolides, quinolones, sulfonamides, tetracyclines and polyether antibiotics, in zebrafish, as well as the combined effects of antibiotic mixtures, to date. Despite a significant amount of the literature describing the impact of single antibiotic exposure, little information exists on the effects of antibiotic mixtures using zebrafish as an animal model. Most of the research papers on this topic have focused on antibiotic toxicity in zebrafish across different developmental stages rather than on their efficacy assessment.Entities:
Keywords: antibiotics; aquatic environment; combined effects; toxicity; zebrafish
Year: 2021 PMID: 34204339 PMCID: PMC8234794 DOI: 10.3390/ph14060578
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Overview of the potential toxicological effects of individual antibiotics on zebrafish, dating from 2005 to the present.
| Class. | Antibiotics | Concentrations | Exposure Period | Lifespan Stages | Effects/Toxicity Observed | Refs. |
|---|---|---|---|---|---|---|
| Aminoglycosides | Netilmicin | 10–1000 ng/mL | 3 days | Embryos | - Cardiotoxicity | [ |
| Gentamicin | Injected with defined volumes of 10 mg/mL | From 55 to 72 and 96 hpf | Larvae | - Nephrotoxicity | [ | |
| 0.2, 1, 2 and 5 μM | 24 h | 5 dpf | - Ototoxicity | [ | ||
| 5, 10 and 20 μM | 24 h | 5 dpf | - Behavioral changes | [ | ||
| 10 μM | 48 h | 3 dpf | - Oculotoxicity | [ | ||
| 0.1–400 μM | Acute and chronic exposure | 5–6 dpf | - Ototoxicity | [ | ||
| Neomycin | 0.16, 1.6, 8 and 16 μM | 24 h | 5 dpf | - Ototoxicity | [ | |
| 125 μM | 1 h | 5 dpf | - Behavioral changes | [ | ||
| 0.1–400 μM | Acute and chronic exposure | 5–6 dpf | - Ototoxicity | [ | ||
| Streptomycin | 0.1–400 μM | Acute and chronic exposure | 5–6 dpf | - Ototoxicity | [ | |
| 0.1, 1 and 10 μg/mL | 10 days | 5 dpf | - Dysbiosis | [ | ||
| Etimicin | Survival test: 2, 5, 10, 20,50, 100, 200 and 500 mg/L | At 24, 48, 72, 96 and 120 hpf | 6 hpf | - Low nephrotoxicity and ototoxicity compared with amikacin and gentamicin | [ | |
| Amikacin | Hatching and toxicity: 750, 1500 or 2000 mg/L | From 1 to 3 dpf | 1 dpf | - More developmental toxicities to the embryos than gentamicin | ||
| β-Lactams | Amoxicillin | 100 mg/L | 7 days | Young zebrafish | - Behavioral changes | [ |
| 0, 75, 128, 221, 380, 654 and 1125 mg/L | 96 h | Embryos | - Developmental toxicity | [ | ||
| 0, 1, 10, 25, 50 and 100 mg/L | Adults | |||||
| Cefotaxime | 10–1000 ng/mL | 3 days | Embryos at 6 hpf and larvae at 3 dpf | - Cardiotoxicity | [ | |
| 0, 10, 20 and 30 mM | 1 day | 5 dpf | - Locomotor toxicity | [ | ||
| Ceftazidime | 0, 6.25, 12.5, 25 mg/L | 96 h | Adult | - Behavioral changes | [ | |
| 10–1000 ng/mL | 3 days | Embryos at 6 hpf and larvae at 3 dpf | - Cardiotoxicity | [ | ||
| Macrolides | Erythromycin, clarithromycin, azithromycin, midecamycin, josamycin | 0, 0.1, 1, 10, 100 and 1000 μM | 48 h until 5 dpf | 3 dpf | - Hepatotoxicity | [ |
| 0, 0.5, 1, 2 | 6 dpf | 3 dpf | - Hepatotoxicity | [ | ||
| acetylspiramycin | 0, 0.25, 0.5, 1 | 6 dpf | 3 dpf | - Hepatotoxicity | [ | |
| Erythromycin | 0, 0.017, 0.034, 0.068, 0.136, 0.272 mM | 96 h | 24 hpf | - Cardiotoxicity | [ | |
| 0, 2, 20, 200 and 2000 μg/L | 96 h | adult | - Abnormal gene expression | [ | ||
| 0, 0.001, 0.01, 0.1, 1 and 10 μg/L | 96 hpf | 2 hpf | - Cardiotoxicity | [ | ||
| Tilmicosin | 0, 0.63, 1.25, 2.5, 5, 10, 20 and 40 mg/L | 4 dpf | 2 dpf | - Developmental toxicity | [ | |
| Quinolones | Ciprofloxacin | 0, 6.25, 12.5, 25 mg/L | 96 h | Adult | - Behavioral changes | [ |
| 5 μg/L | 6–9 dpf | Larvae | - Increased expression of immune system cytokine genes | [ | ||
| Norfloxacin | 0, 2, 20 and 200 μg/L | 3 weeks | Larvae | - Reproductive toxicity | [ | |
| 600, 900, 1200 mg/L | 72 hpf | Embryos | - Neurotoxicity | [ | ||
| Levofloxacin, | 0, 0.1, 0.2, 0.5, 1, 2, 5, 10, 20 mM | 6–72 hpf | Embryos | - Head deformation | [ | |
| Enrofloxacin | 0.01, 1, 100 μg/L | 120 h | Larvae | - Decreased body lengths | [ | |
| Ofloxacin, | 5 μg/L | 20 days | Adult | - Accumulation in liver, skin, muscles and gills | [ | |
| Gatifloxacin, | - 413, 1238, 3713, 4239 mg/L | 24 h | Adult | - Cardiotoxicity | [ | |
| Sulfonamides | Sulfamethoxazole | 0, 0.09, 0.19, 0.39, 0.79, 1.58 mM | 96 h | 24 hpf | - Developmental toxicity | [ |
| 80 and 100 mg/kg body weight per day | 6 weeks | Adult | - Higher digestive enzyme activities | [ | ||
| 0, 50, 100 and 500 μg/L | 14 days | Adult | - Lipid peroxidation | [ | ||
| 260 ng/L | 6 weeks | Adult | - Impair the gut health | [ | ||
| 0, 2, 20 and 200 μg/L | 3 weeks | Larvae | - Developmental toxicity | [ | ||
| 0, 0.1, 1, 10 and 100 μg/L | 120 h | 5 hpf | - Developmental toxicityoxidative stress | [ | ||
| Sulfamethoxazole, | 0, 20, 40, 80 and 160 μg/L | 24 and 168 hpf | Embryos | - Developmental toxicity | [ | |
| Sulfamethazine | 0, 0.2, 20 and 2000 μg/L | 120 hpf | Embryo | - Developmental toxicity | [ | |
| 1: 7 days exposure, | Adult | |||||
| Tetracyclines | Oxytetracycline | 0, 0.1, 10 and 10,000 μg/L | 2 months | Adult | - Behavioral changes (boldness and hyperactivity) | [ |
| 80 and 100 mg/kg body weight per day | 6 weeks | Adult | - Higher digestive enzyme activities | [ | ||
| 1 and 5 ng/L | From 2 hpf to 120 dpf | Embryo | - Thyroid dysfunction | [ | ||
| 0, 75, 100, 150, 300, 600 and 900 mg/L | 96 h | Embryos | - Developmental toxicity | [ | ||
| 0, 1, 10, 25, 50 and 100 mg/L | Adult | |||||
| 0, 0.05, 0.5 and 5 mg/L | 48 h | 72 hpf | - Oxidative stress | [ | ||
| 420 ng/L | 6 weeks | Adult | - Impair the gut health | [ | ||
| 10 μg/L | 5 days and 2 months exposure | Adult | - The effects are partially reversible | [ | ||
| Tetracycline HCl | 0, 1 and 100 μg/L | 1 month | Juvenile | - Body weight increase | [ | |
| 0, 0.1, 1, 10, 100 and 1000 μM | 48 h until 5 dpf | 3 dpf | - Hepatotoxicity | [ | ||
| 0, 2, 10, 20, 200, 2000 and 20,000 μg/L | 96 h | 4 hpf | - Developmental toxicity | [ | ||
| Minocycline | 10–1000 ng/mL | 3 days | Embryos at 6 hpf and larvae at 3 dpf | - Fish died at 0.4 mg/mL | [ | |
| Chlortetracycline | 0, 6.25, 12.5, 25 mg/L | 96 h | Adult | - Behavioral changes | [ | |
| 0, 0.2, 2 and 20 mg/L | 48 h | 72 hpf | - Oxidative stress | [ | ||
| 0, 6.25, 12.5, 25 mg/L | 96 h | Adult | - Behavioral changes | [ | ||
| Polyether antibiotics | Maduramicin | 0, 0.1, 0.5 and 2.5 mg/L | 14 days | Adult | - Oxidative stress | [ |
| 0, 10, 11.89, 14.14, 16.81 and 20 mg/L | 96 h | Adult | - Impact on the survival | |||
| Monensin | 4, 4.34, 4.7, 5.1,5.53 mg/L | 96 h | Adult | - LC50 = 4.76 mg/L | [ | |
| Others | Ceftazidime | 10–1000 ng/mL | 3 days | Embryos at 6 hpf and larvae at 3 dpf | - Cardiotoxicity | [ |
Abbreviations: dpf = days post-fertilization, hpf = hours post-fertilization.
Figure 1Basic behavioral endpoints of the control and DKA exposed groups (6.25, 12.5 and 25 mg/L) obtained from bottom swelling (A) and conditioned place preference (B) tests. The video trials resulting from the behavioral tests were reused in Ethovision XT software (Noldus IT, Wageningen, Netherlands) to generate average heat maps for experiments. Data represent average ± SD (n = 33–36 individuals for bottom swelling test and n = 34–36 individuals for CPP test) evaluated by one way ANOVA (* p < 0.05 and ** p < 0.01) [28].
Figure 2Histopathological changes in adult zebrafish eye (A), brain (B), hepatic (C) and spleen (D) tissues after exposure to a series of DKA concentrations. Arrows in Figure 2A indicate photoreceptor cell cysts and intercellular vacuoles; in Figure 2B the “a arrow” shows the decrease in neuron number, “b arrow” shows ventriculomegaly and “c arrow” shows glial cell proliferation and the formation of a glial scar; in Figure 2C the “a arrow” indicates reduced, swollen and vague hepatocytes, “b arrow” shows hepatic parenchyma vacuolar degeneration and “c arrow” denotes blood accumulation and clot formation; in Figure 2D the “d arrow” shows metachromatic granules. Histopathological observations on these organs were performed with hematoxylin and eosin (HE) staining using a standard protocol. The photographs of the tissues were taken when 3 biological replicates showed a high degree of uniformity. [113,115].
Morphological measurements for F0 female and F1 embryo and larval zebrafish following maternal antibiotic mixture treatment for 4 weeks. All data are expressed as mean ± SD. [116].
| Changes in F0 Female | Antibiotic Concentrations | ||
|---|---|---|---|
| Control | 1 μg/L | 100 μg/L | |
| Body weight (g) | 0.51 ± 0.016 | 0.53 ± 0.015 | 0.56 ± 0.025 |
| Body length (cm) | 3.58 ± 0.029 | 3.55 ± 0.032 | 3.66 ± 0.031* |
| Intestinal weight (g) | 0.02 ± 0.001 | 0.025 ± 0.002 | 0.024 ± 0.001 |
| Ovary weight (g) | 0.07 ±0.004 | 0.084 ± 0.005 | 0.087 ± 0.004 |
|
|
|
|
|
| Egg production (number per parent, 20 individuals) | 490.6 ± 23.09 | 442 ± 134.51 | 397.3 ± 31.39 |
| Egg death rate at birth (% 0 hpf, 3 biological replicates) | 5.09 ± 2.05 | 6.11 ± 3.05 | 17.76 ± 3.3 * |
| Fertilization rate (% 4 hpf, 3 biological replicates) | 73.2 ± 0.73 | 78.6 ± 1.77 | 74.7 ± 2.25 |
| Egg death rate at 120 hpf (%, 3 biological replicates) | 1.7 ± 0.13 | 2 ± 0.26 | 5.9 ± 0.94 * |
| Hatching rate (%, 72 hpf, 3 biological replicates) | 94.5 ± 2.94 | 92.1 ± 6 | 89.4 ± 3.29 |
| F1 body length (mm, 120 hpf, 20 individuals) | 3.91 ± 0.02 | 3.88 ± 0.02 | 3.92 ± 0.02 |
| Displacement distance (mm, 0–10 min, 120 hpf, 20 individuals) | 582.7 ± 106.2 | 678.4 ± 109 | 465.4 ± 58.6 |
Statistical significance defined as p < 0.05, indicated by an asterisk.
Macrolides concentrations measured in effluents of Company 1 and the concentrations of Figure 2. during four seasons [118].
| Antibiotic | Concentration (μg/L) | ||
|---|---|---|---|
| Winter | Spring | ||
| 1 | Azithromycin | 2137 | 3776 |
| 2341 | 5660 | ||
| Erythromycin | 2009 | 1069 | |
| Summer | Autumn | ||
| 2 | Sulfadiazine | 7.1 | 3 |
| Sulfamethazine | 231 | 6.7 | |
| Trimethoprim | 5.4 | 1 | |
| Enrofloxacin | 4.3 | 3.6 | |
| Oxytetracycline | 29 | 10 | |
Overview of the potential biological effects of antibiotics represented as mixtures in zebrafish, dating from 2014 to the present.
| Class | Antibiotics | Mixture Concentrations | Exposure Period | Lifespan Stages | Effects Observed | Refs. |
|---|---|---|---|---|---|---|
| β-Diketones (fluoroquinolones and tetracyclines) | Ofloxacin, | 0, 6.25 and 12.5 mg/L | From embryos (4 hpf) to larvae (90 dpf) stage | Larvae and adult | - Abnormal expression of differentially expressed miRNAs | [ |
| 0, 12.5 and 25 mg/L | From embryos (2hpf) to larvae (5dpf) stage | 72 hpf or 120 hpf | - Ototoxicity | [ | ||
| 0, 6.25 and 12.5 mg/L | 3 months | 90 dpf | - Immunotoxicity (abnormal expression of immune genes and enzymes and variable levels of damage to immune-related organs) | [ | ||
| 0, 6.25, 12.5 and 25 mg/L | 3 months | Embryos at 6 hpf | - Neurotoxicity (behavioral | [ | ||
| FQs: ciprofloxacin, | 0, 25, 50, 100, 200, 300, 400 and 600 mg/L | 6–120 hpf | 72 hpf or120 hpf | - Abnormal hatching | [ | |
| TCs: chlortetracycline and doxycycline | 0, 1.56, 3.13, 6.25, 12.5, 25 and 50 mg/L | |||||
| FQs + TCs | 0, 4.69, 9.38, 18.75, 37.5, 75, 150, 300 and 450 mg/L | |||||
| FQs: | 0, 12.5, 25, 50 mg/L | 6–96 hpf | 144 hpf | - Higher and basal swimming speed | ||
| TCs: | 0, 1.56, 3.13, 6.25 mg/L | |||||
| FQs + TCs | 0, 4.69, 9.38, 18.75 mg/L | |||||
| FQs + TCs | 0, 9.38, 18.75, 37.5, 75, 150 mg/L | 6–72 hpf | 48, 60, 72 hpf | - Decreased heart rate | ||
| FQs + TCs | 0, 45, 60, 95 mg/L | 2–4 months | - | - Severe edema in sarcoplasmic reticulum, melted muscle fiber and edema in mitochondria (skeletal muscle) | ||
| Ciprofloxacin, | 0, 6.25, 12.5 and 25 mg/L | 6 hpf until 144 hpf | 90 dpfwild-type adult zebrafish | - Physiological impairment | [ | |
| Ciprofloxacin, | 0, 18.75, 37.5, 75, 150, and 300 mg/L | From 6 hpf to 120 hpf | Studied every 12 h using a microscope | - Abnormal hatching | [ | |
| 0, 2.34, 9.38 and 37.5 mg/L | From 6 hpf to 96 hpf | Embryos (<72 hpf) and larvae (>72 hpf) | - Locomotor toxicity | |||
| Ciprofloxacin, | 0, 6.25, 12.5 mg/L | From 6 hpf to 90 dpf | 90 dpf | - Physiological impairment | [ | |
| - Abnormal expression of some lncRNAs and their regulating target genes | [ | |||||
| Ciprofloxacin, | 0, 9.38 mg/L | From 6 hpf to 144 hpf | 90 dpf | - 47 differential expression proteins vs. control with 14 up-regulated and 12 down-regulated | [ | |
| 0, 4.69, 9.38, 18.75 and 37.5 mg/L | From 6 hpf to 96 hpf | 120 hpf | - No visible developmental malformation | |||
| 9.38, 45 and 60 and 90 mg/L | From 6 hpf to 90 dpf | 90 dpf | - Changes in creatine kinase activity and creatinine concentration | |||
| 0, 9.38, 18.75, 37.5, 75 and 150 mg/L | From 6 hpf to 72 hpf | 48,60 and 72 hpf | - Decreased heart rate | |||
| 0, 18.75, 37.5, 75, 150, 300 and 450 mg/L | From 6 hpf to 120 hpf | 72 hpf120 hpf | - 72 hpf EC50 for hatching rate = 130.3 mg/L | [ | ||
| 0, 45, 60 and 90 mg/L | 60 dpf | 7, 14, 21 days | - Changes in creatine kinase activity and creatinine concentration | |||
| 9.38 mg/L | From 6 hpf to 6 days | 90 dpf | - Serious liver damage | [ | ||
| 2.34, 9.38 and 37.5 mg/L | - Oxidative stress (SOD and GSH) | |||||
| Sulfonamides (binary mixtures) | Sulfamethoxazole, | 0, 20, 40, 80 and 160 μg/L | 24 and 168 hpf | Embryos | - Developmental toxicity | [ |
| Sulfonamides, β-lactams, tetracyclines and quinolones | Sulfamonomethoxine | 0.01, 1 and 100 μg/Lin equal proportions | 120 h | Embryos at 4 hpf | - No significant differences in the mortality | [ |
| Macrolides, amphenicols and sulfonamides | Clarithromycin, florfenicol, sulfamethazine | 0.1 mg/L | 96 h | Embryo | - No visible morphological changes | [ |
| - | 5 dpf | |||||
| 72 h | Adult | |||||
| Macrolides, lincosamides, quinolones, sulfonamides, tetracyclines and other | Clarithromycin, erythromycin, roxithromycin, lincomycin, ciprofloxacin, enrofloxacin, norfloxacin, ofloxacin, sulfadiazine, sulfamethazine, sulfamethoxazole, trimethoprim, oxytetracycline, chlortetracycline and tetracycline | 0.1 and100 μg/L | 4 weeks | 150 dpf gravid fish | - Reproductive effects | [ |
| β-lactams, aminoglycosides and macrolides | Ampicillin, | Mixture of 100 μg/mL AMP, 5 μg/mL KAN | 2 weeks | Adult male zebrafish | - Alter the intestinal microbiome | [ |
Abbreviations: TEM = transmission electron microscopy, ROS = reactive oxygen species, hpf = hours post-fertilization, dpf = days post-fertilization, FQs = fluoroquinolones, TCs = tetracyclines, EC50 = half maximal effective concentration, LC50 = lethal 50, AMP = ampicillin, KAN = kanamycin, AMB = amphotericin B, SBS = short bowel syndrome.